Tsuchimoto Kim R sold $290K of MNPR

Tsuchimoto Kim R sold 4,090 shares of Monopar Therapeutics (MNPR) at an average of $70.92 ($70.10–$72.21, $0.29M total) across 4 trades over 2026-11-02 to 2026-11-04 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Tsuchimoto Kim R
Published Nov 5, 2026, 1:15 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 1:35 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$MNPR
Bearish
high confidence
Mentioned
$MNPR
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MNPRBearishLow
01

Why it matters

The director's exit reduces insider ownership to zero, potentially affecting investor perception and short‑term price action.

02

Market read

Primary insider sale filing; modest size but may trigger short‑term sell pressure.

03

What to watch

The 10b5‑1 plan pre‑arranges sales, which may mitigate negative perception; also, the sale size is modest relative to market cap.

Relevance 3/10Novelty 3/10Timing: post‑market filing today

Background

SEC Form 4 filing discloses insider transactions; this is the first public report of the director's sale.

Company-level read

Ticker impact

$MNPRBearishHigh confidence
Context

Director Tsuchimoto Kim R sold 4,090 shares for $290K via a 10b5‑1 plan, reducing holdings to zero.

Expected impact

likely downward pressure as the market prices in the insider sell

Evidence & confidence

Form 4 is a primary source; a director exiting with a sizable block often triggers short‑term sell‑off.

Market effects

Minimal; biotech sector may view the sale as a company‑specific signal rather than a broader trend.

None; the filing is U.S.‑focused.

Low; no macro or global implications.

Counterpoint

The sale could be a routine liquidity event unrelated to fundamentals, so the stock may remain stable.

Key entities

  • Monopar Therapeutics

    Biotech firm listed on NASDAQ under ticker MNPR.

  • Tsuchimoto Kim R

    Director of Monopar Therapeutics who executed the sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$MNPRMed

Monopar Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Updates

Monopar Therapeutics (MNPR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Monopar Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Updates Wilmette, IL, November 12, 2026 – Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical‐stage biopharmaceutical company developing innovative t

$MNPRMedAI 8/10

Monopar presents Wilson disease trial data at liver conference

Monopar Therapeutics (MNPR) presented Phase 3 FoCus trial data for Wilson disease at a liver conference. Key findings include high rates of cirrhosis, neurologic, and psychiatric symptoms among patients. ALXN1840, its investigational therapy, showed positive long-term data. The trial is the largest randomized controlled study in Wilson disease.

$MNPRMedAI 8/10

Monopar Presents Data Highlighting Residual Disease Burden in Treatment-Experienced Wilson Disease Patients and Long-Term Molybdenum Safety Data for ALXN1840 at AASLD – The Liver Meeting® 2026

Monopar Therapeutics (MNPR) presented data from its Phase 3 FoCus trial at AASLD 2026, showing significant disease burden in Wilson disease patients, including cirrhosis, neurologic, and psychiatric symptoms. ALXN1840, Monopar's investigational therapy, demonstrated long-term safety with neutral molybdenum balance and normal uric acid levels over six years.

$MNPRLow

Monopar Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates

Monopar Therapeutics (MNPR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Monopar Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates Wilmette, IL, August 12, 2026 – Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical‐stage biopharmaceutical company developing innovative tr

$MNPRMedAI 8/10

Monopar Presents Phase 2 ALXN1840 Data Demonstrating Liver Disease Stabilization and Neurologic Improvement in Treatment-Experienced Wilson Disease Patients at EASL 2026

Monopar Therapeutics presented Phase 2 ALXN1840 (tiomolibdate choline) data at EASL 2026 for treatment-experienced Wilson disease patients. In an open-label, multicenter 48-week trial (29 patients; 24 with paired biopsies), histology showed stabilization or improvement in multiple liver measures, with no statistically significant change in hepatic copper. The company also reported significant improvements in UWDRS Part III, CGI, and EQ-5D UK, with generally nonserious Grade 1–2 adverse events.